Aspirin therapy is of proven value in treatment of acute MI as well as long-term use in patients with a wide range of prior manifestations of cardiovascular disease. The more widespread use of aspirin in these patient categories will contribute to reductions in cardiovascular disease morbidity and mortality. Additional data are needed from randomized trials in primary prevention, particularly the ongoing Women's Health Study, to formulate rational policy recommendations for use of aspirin in apparently healthy people. In the meantime, use of aspirin in primary prevention of MI should remain an individual clinical judgment. Aspirin therapy should always be an adjunct, not an alternative, to management of other risk factors.
- AHA Medical/Scientific Statements
- Cardiovascular disease
- Myocardial infarction